DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
DiaMedica Therapeutics (Nasdaq: DMAC) said President and CEO Rick Pauls will participate in the Jefferies Global Healthcare Conference in London on November 17-20, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Mr. Pauls will deliver a corporate presentation and participate in one-on-one investor meetings during the conference.
Details
Jefferies Global Healthcare Conference in
Time below is listed in Greenwich Mean Time (GMT)
Corporate Presentation:
Date: Thursday, November 20, 2025
Time: 10:00-10:25 AM
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein to be clinically studied in
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110063933/en/
Corporate Contact:
Scott Kellen, Chief Financial Officer
(763) 496-5118 | skellen@diamedica.com
Investor Contact:
Mike Moyer, Managing Director, LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contact:
Madelin Hawtin, LifeSci Communications
mhawtin@lifescicomms.com
Source: DiaMedica Therapeutics Inc.